Gemini Therapeutics, Inc. /DE
Completed
Follow
Detailed Information
Information on this SPAC.
- Sponsors
- IPO Size
- $100M
- Underwriters
- Focus
- Biotech
- SEC Filings
- 1816736
- Public Embarc Page
- https://embarc.com/capital/spac/1816736/FSDC/gemini-therapeutics-inc-de
- IPO Ticker
- FSDC
SPAC Leadership
Information on the SPAC leadership.
- President, Chief Executive Officer and DirectorJim Tananbaum
- Chief Financial OfficerDennis Ryan
- Vice President and DirectorMichael Rome
- DirectorVikram Bajaj
- DirectorRobert Carey
- Dan Dubin
- DirectorDeepa Pakianathan
- DirectorDaniel Dubin
Target Information
Information on the SPAC target for merger.
- Company
- Gemini Therapeutics
- New Ticker
- GMTX
- Description
- Gemini Therapeutics is "a clinical stage precision medicine company developing innovative treatments for age-related macular degeneration (AMD) and linked ocular disorders by developing drugging strategies that are matched to specific genetic mutations found in patients with high clinical unmet need."